TCEAL7

TCEAL7 is a nuclear transcriptional regulatory protein that functions as a tumor suppressor and myogenic differentiation factor by modulating multiple oncogenic and developmental signaling pathways. It represses c-Myc transcriptional activity at E-box-containing promoters (cyclin D1, ODC, hTERT) through association with Myc target promoter regions, and independently inhibits NF-κB p65 transcriptional activity at target gene promoters (IL-6, IL-8) without affecting cytoplasmic NF-κB signaling or IκB degradation (PMID:18806825, PMID:19966855, PMID:20454512). TCEAL7 also blocks β-catenin nuclear translocation to suppress Wnt signaling, physically interacts with Cdk1 to reduce phosphorylation of mTOR pathway substrates (4E-BP1, p70S6K1) in skeletal muscle, and is transcriptionally activated by MRFs through conserved E-box motifs as well as by Mef2c/Creb1 complexes during myogenic differentiation (PMID:31402274, PMID:37047236, PMID:20307260, PMID:35816819). Its expression is epigenetically silenced in cancer by promoter CpG hypermethylation and post-transcriptionally repressed by miR-301a and miR-18b delivered via exosomes, and re-expression induces cell death and reduces colony formation (PMID:15870691, PMID:34853307).

1. 2005 High

   Establishing TCEAL7 as a tumor suppressor silenced by epigenetic mechanisms resolved why this X-linked gene is lost in ovarian cancer: promoter CpG methylation directly suppresses transcription, and re-expression induces cell death.

   Evidence Bisulfite sequencing, in vitro methylation/demethylation of promoter constructs, 5-aza-2'-deoxycytidine treatment, and colony formation assays in ovarian cancer cell lines

   PMID:15870691

   Open questions at the time

   • Mechanism by which TCEAL7 re-expression induces cell death was not identified
   • Whether methylation-mediated silencing extends to other cancer types was not tested
   • Direct transcriptional targets of TCEAL7 were unknown
2. 2008 High

   Identification of TCEAL7 as a repressor of c-Myc transcriptional activity provided the first mechanistic link to a specific oncogenic transcription factor, showing TCEAL7 associates with Myc E-box sequences at the cyclin D1 promoter and inhibits Myc-Max DNA-binding activity.

   Evidence ChIP at cyclin D1 promoter, Myc-Max DNA-binding assay, ODC promoter-luciferase reporter, anchorage-independent growth assay

   PMID:18806825

   Open questions at the time

   • Whether TCEAL7 directly binds DNA or acts through a co-repressor complex was unresolved
   • Physical interaction between TCEAL7 and Myc-Max was not demonstrated
3. 2009 High

   Discovery that TCEAL7 independently represses NF-κB signaling at the transcriptional level — reducing p65 and p300 recruitment to target promoters without affecting cytoplasmic IκB degradation — established a second major oncogenic pathway controlled by TCEAL7.

   Evidence shRNA knockdown, NF-κB luciferase reporter, EMSA, ChIP for p65 and p300 at IL-8/IL-6 promoters, IKK inhibitor rescue

   PMID:19966855

   Open questions at the time

   • Whether TCEAL7 physically interacts with p65 or p300 was not determined
   • Mechanism by which TCEAL7 prevents p65/p300 recruitment to chromatin remained unclear
4. 2010 High

   Demonstration that MRFs directly transactivate Tceal7 through conserved E-box motifs in vivo, and that Tceal7 overexpression promotes myoblast differentiation while reducing proliferation, placed TCEAL7 as a direct effector of the myogenic transcription program.

   Evidence Transgenic LacZ reporter in mouse embryos, E-box mutagenesis, EMSA, ChIP, C2C12 overexpression with proliferation/differentiation readouts

   PMID:20307260

   Open questions at the time

   • Downstream transcriptional targets of TCEAL7 in muscle were not defined
   • Loss-of-function phenotype in muscle development was not tested
5. 2010 Medium

   Extension of the c-Myc repressor function to hTERT regulation in ALT cells showed TCEAL7 competitively inhibits c-Myc binding at the hTERT promoter, broadening the set of Myc target genes subject to TCEAL7 repression.

   Evidence c-Myc ChIP at hTERT promoter, TCEAL7 expression modulation with hTERT promoter activity readout in ALT and telomerase-positive cells

   PMID:20454512

   Open questions at the time

   • Direct physical competition between TCEAL7 and c-Myc at chromatin was not shown
   • Relevance to telomere maintenance in vivo was not tested
6. 2019 Medium

   Identification of TCEAL7 as a negative regulator of Wnt/β-catenin signaling — blocking β-catenin nuclear translocation — added a third oncogenic pathway controlled by TCEAL7 and revealed exosomal miR-301a as a post-transcriptional silencing mechanism.

   Evidence Luciferase 3'UTR reporter for miR-301a, β-catenin subcellular fractionation, TCEAL7 overexpression rescue of radioresistance in glioma cells

   PMID:31402274

   Open questions at the time

   • Molecular mechanism by which TCEAL7 prevents β-catenin nuclear import was not determined
   • Whether TCEAL7 physically interacts with β-catenin was not tested
7. 2021 Medium

   Demonstration that exosomal miR-18b from cancer-associated fibroblasts represses TCEAL7 to activate NF-κB/Snail/EMT linked the NF-κB repressor function to an in vivo metastasis phenotype in breast cancer.

   Evidence Luciferase 3'UTR reporter for miR-18b, NF-κB pathway readout, Snail nuclear localization, EMT markers, mouse xenograft metastasis model

   PMID:34853307

   Open questions at the time

   • Whether TCEAL7 directly regulates Snail transcription or acts solely through NF-κB was not resolved
   • Contribution of TCEAL7 versus other miR-18b targets to metastasis was not deconvolved
8. 2022 Medium

   Mapping a Mef2c–Creb1–MyoD triple complex that synergistically transactivates the Tceal7 promoter through Mef2 and CRE motifs refined understanding of how Tceal7 is induced during skeletal muscle differentiation.

   Evidence Transcriptional reporter assays with Mef2/CRE motif mutagenesis, protein–protein interaction mapping between Mef2c and Creb1

   PMID:35816819

   Open questions at the time

   • ChIP confirmation of Mef2c/Creb1 occupancy at the endogenous Tceal7 promoter was not shown
   • Functional requirement of each motif in vivo was not tested
9. 2023 Medium

   Discovery that Tceal7 physically interacts with Cdk1 and that transgenic overexpression reduces phosphorylation of mTOR/Cdk substrates and impairs postnatal muscle fiber growth identified a non-transcriptional mechanism through which Tceal7 regulates cell growth.

   Evidence Co-immunoprecipitation for Tceal7–Cdk1 in skeletal muscle, transgenic MCK-HA-Tceal7 mouse, immunoblotting for p-4E-BP1/p-p70S6K1/Cdk substrates

   PMID:37047236

   Open questions at the time

   • Reciprocal Co-IP or in vitro binding assay to confirm direct Tceal7–Cdk1 interaction was not provided
   • Whether Tceal7 inhibits Cdk1 kinase activity directly or acts as a scaffolding/sequestering factor is unknown
   • Loss-of-function muscle phenotype was not examined

• Key unresolved questions include the structural basis for TCEAL7's multi-pathway transcriptional repression (whether it directly binds DNA or acts exclusively through protein–protein interactions with Myc, p65, or β-catenin), the identity of a core TCEAL7-containing repressor complex, and the in vivo consequence of Tceal7 genetic loss in both tumor suppression and muscle development.
• No structural or biochemical data exist for TCEAL7 protein
• No Tceal7 knockout mouse or genetic loss-of-function model has been reported
• Whether the Myc-repressor, NF-κB-repressor, Wnt-inhibitory, and Cdk1-binding functions reflect a unified molecular mechanism is unknown